AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
NORTH CHICAGO, Ill., Aug. 21, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World Conference on Lung Cancer (WCLC), including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The presentations span clinical, translational and real-world data across next-generation immunotherapies and targeted antibody-drug conjugates (ADCs), designed to generate insights into treatment burden, patient experience and biomarker identification that may help inform future research.
"Our strategy in lung cancer is focused on building a complementary pipeline that brings together next-generation immunotherapies and targeted antibody-drug conjugates with the potential to address different aspects of tumor biology," said Daejin Abidoye, M.D., vice president and therapeutic area head of oncology, solid tumor and hematology at AbbVie. "Exploring the PD-1/VEGF approach represented by ABBV-1480 and the c-Met targeting by Temab-A are important elements of that strategy and may provide a foundation for potential novel combinations as we work to develop more tailored treatment approaches for people living with lung cancer."
Advancing Novel Therapies Across Various Modalities in NSCLC
Multiple presentations across AbbVie's NSCLC portfolio will showcase new studies and data analyses spanning multiple treatment modalities, highlighting first-line treatment approaches, patient experience and biomarker-informed research.
Clinical Data Showcasing the Potential of ABBV-706 in SCLC
ABBV-706 is an investigational SEZ6-targeted ADC with a Top1i payload, being evaluated in SCLC. Presentations at WCLC include research that further characterizes the program and the potential role of SEZ6 in SCLC.
Additional details on key presentations are available below, and the full WCLC 2026 abstracts are available online.
For information about AbbVie's clinical trial efforts in lung cancer, please visit clinicaltrials.gov.
Title
Date/Time
Session
Abstract Number
Radiomic Biomarkers on Baseline CT
Scans for Predicting Response to
Teliso-V in NSCLC: A Machine
Learning Approach
Monday,
September 14
10:30AM-12:00PM KST
Poster
Session: P2.077-248.
Pathology and
Biomarkers
P2.137.
Telisotuzumab Adizutecan and PD-1 Inhibitor
in Untreated Advanced Non-Squamous
Non-Small Cell Lung Cancer: A Phase
1b/2 Study
Monday,
September 14
10:30AM-12:00PM KST
Poster
Session: P2.304-390.
Clinical Trials in
Progress
P2.374.
Efficacy and Safety of ABBV-706 Versus
Standard of Care in Relapsed/Refractory
Small Cell Lung Cancer: A Phase 3 Study
Monday,
September 14
10:30AM-12:00PM KST
Poster
Session: P2.304-390.
Clinical Trials in
Progress
P2.377.
A Phase 3, Randomized, Double-Blind Trial
of RC148 (ABBV-1480) Plus Chemotherapy
in First-Line Squamous Non-Small-Cell
Lung Cancer
Monday,
September 14
10:30AM-12:00PM KST
Poster
Session: P2.304-390.
Clinical Trials in
Progress
P2.379.
Peripheral Neuropathy With Teliso-V in
c-Met- Protein Overexpressing NSCLC
in LUMINOSITY: Clinical Characteristics
and PROs
Monday,
September 14
2:17-2:25 PM KST
Poster
Session: PT2.01.
Metastatic
NSCLC –
Antibody-Drug
Conjugate and
Cytotoxic
Therapy
PT2.01.05.
Telisotuzumab vedotin Demonstrates Potent
Antitumor Efficacy in Preclinical Models of
Diffuse Pleural Mesothelioma
Monday,
September 14
2:17-2:25 PM KST
Poster
Session: PT2.05.
Mesothelioma,
Thymoma, and
Other Thoracic
Tumors
PT2.05.05.
Hematologic and Gastrointestinal Toxicity of
ABBV-706 in Advanced Solid Tumors: Safety
Profile from the First-in-Human Study
Tuesday,
September 15
9:30-11:00 AM KST
Poster
Session: P3.282-354.
Small Cell Lung
Cancer and
Neuroendocrine
Tumors
P3.316.
SEZ6 Is Expressed Across Major Clinical and
Demographic Groups of SCLC Patients:
Evidence From a US Clinicogenomic
Database
Tuesday,
September 15
9:30 AM-11:00 AM KST
Poster
Session: P3.282-354.
Small Cell Lung
Cancer and
Neuroendocrine
Tumors
P3.340.
RC148 (ABBV-1480, PD-1/VEGF Bispecific
Antibody) Plus Chemotherapy in First-Line
Locally Advanced or Metastatic Non-Small-
Cell Lung Cancer
Tuesday,
September 15
12:52-1:02 PM KST
Oral Presentation
Session: OA14.
The Breakthrough
Immunotherapy
for Advanced
NSCLC
OA14.01.03.
High Burden and Limited Evidence in Late-
Line ES-SCLC: A Structured Review of
Clinical and Humanistic Outcomes
-
E-Poster
EP13 Small Cell
Lung Cancer and
Neuroendocrine
Tumors
EP13.05.
Pneumonitis/Interstitial Lung Disease in the
First-in-Human ABBV-706 Study: Incidence,
Management, and Risk Factors
-
E-Poster
EP13 Small Cell
Lung Cancer and
Neuroendocrine
Tumors
EP13.32.
Telisotuzumab adizutecan (Temab-A) and ABBV-706 are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies.
AbbVie holds exclusive rights from RemeGen to develop, manufacture, and commercialize ABBV-1480 outside of the Greater China territory.
Emrelis™ (telisotuzumab vedotin-tllv) is an approved medicine being investigated for additional uses. Safety and efficacy have not been established for these unapproved additional uses.
U.S. Prescribing Information for AbbVie Medicines
Please see full Prescribing Information for EMRELIS ™ (telisotuzumab vedotin-tllv).
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References:
Global Media:
Sourojit (Jit) Bhowmick, Ph.D.
[email protected]
Investors:
Liz Shea
[email protected]
SOURCE AbbVie